Off-Label Use of Atypical Antipsychotics: An Update
Results and Summary of Benefits: Atypical Antipsychotics for Eating Disorders (Anorexia Nervosa)
Olanzapine was studied in 3 trials with a total of 84 patients, using body mass index (BMI) at 1 and 3 months as the outcome measure. No statistically significant difference between patients treated with olanzapine and those in the placebo group was detected. The strength of evidence in support of this finding is moderate. Likewise, quetiapine was studied in 1 trial of 27 patients, measuring BMI at 3 months as the outcome. No statistically significant difference between treated and control groups was detected. The strength of evidence for this finding is low. In conclusion, olanzapine and quetiapine do not increase BMI in patients with anorexia nervosa.
Keywords: antipsychotics | atypical antipsychotics | off-label | second generation | anorexia nervosa | BMI | olanzapine | quetiapine
- Maglione M, Ruelaz Maher A, Hu J, et al. Off-Label Use of Atypical Antipsychotics: An Update. Comparative Effectiveness Review No. 43 (Prepared by the Southern California RAND Evidence-based Practice Center under Contract No. HHSA 290-2007-10062-I). Rockville, MD: Agency for Healthcare Research and Quality; September 2011. AHRQ Publication No. 11(12)-EHC087-EF. Available at www.effectivehealthcare.ahrq.gov/offlabelantipsych.cfm.
Your slide tray is being processed.